Activation of OBSCN-AS1 by CRISPR in triple-negative breast cancer can effectively restore the expression of OBSCN, inhibit the migration, invasion, and metastasis of tumor cells in vitro, and may become a therapeutic target for triple-negative breast cancer [22]. This evidence concerns the gene OBSCN and neoplasm.